arrow
S

Susan E. Critchlow

AstraZeneca
H指数:33
被引数:7,687

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer

KEAP1和STK11/LKB1突变增强KRAS突变非小细胞肺癌对ATR抑制的易感性

2025-07-100
OAAI
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer

FOXO3与FOXM1的相互作用影响PIK3CA及PIK3CA/PTEN变异的雌激素受体阳性乳腺癌对AKT抑制的敏感性。

2025-04-220
OA
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor
2024-12-100
PRE
Integrative dynamic MultiOMICs analysis identifies cell cycle and DNA damage response phenotypes as downstream consequences of using the PRMT5 inhibitor AZD3470
2024-04-050
PRE
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

下一代口服选择性雌激素受体降解剂Camizestrant (AZD9833) 抑制ER乳腺癌生长并克服内分泌和CDK4/6抑制剂抗性

2023-09-1916
OAAI
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models (vol 62, pg 6540, 2019)
2023-06-210
PRE
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

发现临床候选药物AZD0095,一种用于肿瘤学的单羧酸转运蛋白4 (MCT4) 的选择性抑制剂

2022-12-1623
PRE
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper br
2022-08-0574
OAAI
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
2021-09-2781
PREAI
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
2021-03-3011
OA
Reversing PARP inhibitor resistance by targeting the replication stress response
2019-07-010
PRE
Biomarkers for inhibitors of the replication stress response proteins WEE1 and ATR in triple negative breast cancer
2019-07-011
PRE
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models
2019-06-1422
PREAI